Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMCR
stocks logo

IMCR

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
92.43M
+22.58%
-0.220
-4.17%
95.26M
+18.71%
-0.267
-257%
97.26M
+15.71%
-0.280
-40.4%
Estimates Revision
The market is revising Upward the revenue expectations for Immunocore Holdings plc (IMCR) for FY2025, with the revenue forecasts being adjusted by 5.07% over the past three months. During the same period, the stock price has changed by 27.24%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-58.72%
In Past 3 Month
Stock Price
Go Up
up Image
+27.24%
In Past 3 Month
9 Analyst Rating
up Image0
Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 64.89 USD with a low forecast of 33.00 USD and a high forecast of 100.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 36.150
sliders
Low
33.00
Averages
64.89
High
100.00
up Image0
Current: 36.150
sliders
Low
33.00
Averages
64.89
High
100.00
Deutsche Bank
initiated
$65
2025-05-27
Reason
Deutsche Bank
Price Target
$65
2025-05-27
initiated
Reason
Oppenheimer
Oppenheimer
Outperform
maintain
$85 -> $86
2025-05-08
Reason
Oppenheimer
Oppenheimer
Price Target
$85 -> $86
2025-05-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Immunocore to $86 from $85 and keeps an Outperform rating on the shares. The firm notes that on Wednesday, the company announced strong Q1 sales for KIMMTRAK, with revenue of $93.9M vs. OPCO/Consensus of $88M/$87M, +12% from the prior quarter.
JP Morgan
Jessica Fye
Buy
Maintains
$54 → $50
2025-04-14
Reason
JP Morgan
Jessica Fye
Price Target
$54 → $50
2025-04-14
Maintains
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$71
2025-04-10
Reason
Needham
Gil Blum
Price Target
$71
2025-04-10
Reiterates
Strong Buy
Reason
Mizuho
Graig Suvannavejh
Hold
Maintains
$38 → $33
2025-04-07
Reason
Mizuho
Graig Suvannavejh
Price Target
$38 → $33
2025-04-07
Maintains
Hold
Reason
Mizuho lowered the firm's price target on Immunocore to $33 from $38 and keeps a Neutral rating on the shares. The firm's thesis on Immunocore remains unchanged, and while Mizuho views Immunocre as a pioneer and leader in the development of T-cell receptor-based therapeutics for cancer, overall lack of meaningful clinical newsflow over the next 12-15 months for the company makes it difficult to see why its shares should outperform.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$100
2025-03-12
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$100
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunocore Holdings PLC (IMCR.O) is -38.65, compared to its 5-year average forward P/E of -44.78. For a more detailed relative valuation and DCF analysis to assess Immunocore Holdings PLC 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-44.78
Current PE
-38.65
Overvalued PE
20.18
Undervalued PE
-109.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-60.71
Current EV/EBITDA
-17.35
Overvalued EV/EBITDA
82.98
Undervalued EV/EBITDA
-204.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
16.59
Current PS
4.61
Overvalued PS
32.55
Undervalued PS
0.64

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

IMCR News & Events

Events Timeline

(ET)
2025-05-07
07:15:39
Immunocore reports Q1 EPS 10c, consensus (40c)
select
2025-02-26 (ET)
2025-02-26
07:09:21
Immunocore reports Q4 EPS (47c), consensus (16c)
select
2025-01-10 (ET)
2025-01-10
06:25:33
Immunocore reports cash, equivalents of $820M as of December 31
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.5
06-30Globenewswire
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

  • Partnership Announcement: Er-Kim has been appointed by Immunocore as the distribution and commercialization partner for KIMMTRAK, a treatment for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in Turkey and several regions including the Middle East and CIS.

  • About Uveal Melanoma: Uveal melanoma is a rare and aggressive eye cancer with a poor prognosis for patients with advanced stages; KIMMTRAK offers a new treatment option aimed at improving outcomes for these patients.

Preview
9.0
06-23NASDAQ.COM
FDA Extends INCY's Application for Opzelura Label Expansion

  • FDA Review Extension: Incyte's supplemental new drug application for ruxolitinib cream, aimed at treating mild to moderate atopic dermatitis in children aged 2-11, has had its review period extended by three months to September 19, 2025, due to the need for additional data review.

  • Market Performance and Drug Portfolio: Despite a slight decline in shares year-to-date, Incyte is expanding its portfolio beyond its lead drug Jakafi, with recent approvals of other drugs like Monjuvi and Zynyz contributing to growth, although competition and patent expiration concerns for Jakafi remain significant challenges.

Preview
8.5
06-20NASDAQ.COM
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

  • CureVac Acquisition by BioNTech: CureVac's shares surged 40.8% following a definitive agreement for BioNTech to acquire the company in an all-stock deal valued at approximately $1.25 billion, with shareholders expected to own 4-6% of BioNTech post-transaction.

  • Strategic Expansion for BioNTech: The acquisition will enhance BioNTech's capabilities in mRNA-based cancer immunotherapies and expand its oncology pipeline, complementing its existing strengths and recent collaborations, including a significant partnership with Bristol Myers Squibb.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immunocore Holdings PLC (IMCR) stock price today?

The current price of IMCR is 36.15 USD — it has increased 1.13 % in the last trading day.

arrow icon

What is Immunocore Holdings PLC (IMCR)'s business?

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

arrow icon

What is the price predicton of IMCR Stock?

Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 64.89 USD with a low forecast of 33.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immunocore Holdings PLC (IMCR)'s revenue for the last quarter?

Immunocore Holdings PLC revenue for the last quarter amounts to 93.88M USD, increased 33.16 % YoY.

arrow icon

What is Immunocore Holdings PLC (IMCR)'s earnings per share (EPS) for the last quarter?

Immunocore Holdings PLC. EPS for the last quarter amounts to 0.10 USD, decreased -120.41 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immunocore Holdings PLC (IMCR)'s fundamentals?

The market is revising Upward the revenue expectations for Immunocore Holdings plc (IMCR) for FY2025, with the revenue forecasts being adjusted by 5.07% over the past three months. During the same period, the stock price has changed by 27.24%.
arrow icon

How many employees does Immunocore Holdings PLC (IMCR). have?

Immunocore Holdings PLC (IMCR) has 493 emplpoyees as of July 18 2025.

arrow icon

What is Immunocore Holdings PLC (IMCR) market cap?

Today IMCR has the market capitalization of 1.80B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free